Due to the low level of labetalol in breast milk, the infant’s intake is low and does not cause any adverse effects in breastfed full-term infants. Most infants do not require special attention. However, special attention should be paid to certain issues in premature infants. The amount of Beta-blockers excreted into breast milk depends largely on their protein binding. Less binding makes it more likely to be excreted into breast milk. The accumulation of the drug in the infant is related to the proportion excreted in the urine. Labetalol is 50% protein bound, 5% is excreted by the kidneys, has a moderate half-life, and has a low risk of drug accumulation in infants. Intravenous administration of labetalol increases serum prolactin in men and non-lactating women, with women having greater increased levels. Oral labetalol does not increase serum prolactin. In a mother who has started breastfeeding, prolactin levels do not affect her ability to breastfeed.